A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System Atrophy.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2011
At a glance
- Drugs AZD 3241 (Primary)
- Indications Multiple system atrophy
- Focus Therapeutic Use
- 08 Jun 2011 New trial record